U.S. Chemicals Stock News

NasdaqGS:HTO
NasdaqGS:HTOWater Utilities

Institutional Shifts Put H2O America’s Valuation And Stability In Focus

Ausbil Investment Management has disclosed H2O America (NasdaqGS:HTO) as its largest portfolio holding. ATLAS Infrastructure Partners has reported owning more than 10% of H2O America. These institutional ownership changes highlight a shift in H2O America's shareholder base that has not been widely discussed. For you as an investor, concentrated positions like Ausbil’s and a stake of more than 10% from ATLAS Infrastructure Partners can change how H2O America is viewed in the market. Large,...
NasdaqGS:CATY
NasdaqGS:CATYBanks

Congressman Cisneros Buys Cathay General Shares As Valuation Gap Persists

U.S. Representative Gilbert Ray Cisneros, Jr. recently disclosed a personal purchase of Cathay General Bancorp (NasdaqGS:CATY) shares. The transaction adds a new political figure to the shareholder base of Cathay General Bancorp, which has previously drawn attention for executive insider activity. The purchase comes with Cathay General Bancorp shares trading around $53.47. Cathay General Bancorp, trading under NasdaqGS:CATY, has seen its shares at about $53.47, with recent returns of 5.7%...
NYSE:IMAX
NYSE:IMAXEntertainment

IMAX CEO Takes Medical Leave While Shares Trade Below Valuation Targets

IMAX (NYSE:IMAX) announced that CEO Richard Gelfond has taken a temporary medical leave of absence. The company has described the move as temporary, with existing leadership expected to oversee operations during his absence. IMAX runs a global network of premium large format cinemas and technology partnerships, placing it at the center of the theatrical side of the film industry. The company is closely tied to major studio release schedules and audience demand for big screen experiences...
NasdaqGS:LOT
NasdaqGS:LOTAuto

Can Lotus Technology (LOT) Turn Shrinking Revenue And New Hyper SUV Ambitions Into Strategic Strength?

Lotus Technology Inc. has reported its fourth-quarter and full-year 2025 results, with revenue falling to US$163.34 million for the quarter and US$519.10 million for the year, while net losses narrowed to US$85.77 million and US$464.22 million respectively compared with the prior year. Against this backdrop of shrinking sales but smaller losses, Lotus has also launched its new “For Me” hyper SUV in Beijing, showcasing its X-Hybrid Architecture and underscoring a push toward high-performance...
NYSE:UNF
NYSE:UNFCommercial Services

Will Rising Sales and Squeezed Margins Shift UniFirst's (UNF) Profitability Narrative

In the past quarter, UniFirst Corporation reported second-quarter 2026 sales of US$622.51 million, up from US$602.22 million a year earlier, while net income declined to US$20.48 million and diluted earnings per share from continuing operations fell to US$1.13. Over the first six months of fiscal 2026, UniFirst grew sales to US$1,243.82 million but saw net income and diluted earnings per share from continuing operations fall to US$54.85 million and US$3.02 respectively, highlighting that...
NasdaqGS:NEOG
NasdaqGS:NEOGMedical Equipment

Neogen Reshapes Portfolio Around Food Safety With Divestitures And Job Cuts

Neogen has agreed to sell its Genomics business to Zoetis as part of a wider portfolio reshaping. The company has completed the divestiture of its Cleaners and Disinfectants business. Neogen is implementing a major restructuring, including a 10% global headcount reduction. These actions concentrate the business around its core Food Safety segment and streamline operations. For investors watching NasdaqGS:NEOG, these moves come after a mixed share price history. The stock is at $9.42, with a...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

Is It Too Late To Consider Jazz Pharmaceuticals (JAZZ) After A 93% One Year Rally?

If you are wondering whether Jazz Pharmaceuticals at around US$194.20 is still offering value after a strong run, the key is to look closely at what the current price actually reflects. The stock has posted returns of 3.9% over the last 7 days, 8.8% over 30 days, 12.2% year to date, and 93.2% over the past year, which naturally raises questions about how much of the story is already priced in and how risk is being perceived. Recent attention on Jazz Pharmaceuticals has centered on its...
NasdaqGS:MEDP
NasdaqGS:MEDPLife Sciences

Medpace Lawsuits And CEO Sales Test Growth Story And Valuation

Medpace Holdings (NasdaqGS:MEDP) is facing multiple shareholder class action lawsuits tied to alleged false and misleading statements about its book to bill ratio and backlog cancellation rates. Investors claim they suffered losses after company disclosures, with recent insider stock sales by the CEO shortly before negative updates adding to concerns. The litigation focuses on whether management provided overly optimistic projections that did not align with internal business conditions. For...
NasdaqGM:WINA
NasdaqGM:WINASpecialty Retail

Is It Too Late To Consider Winmark (WINA) After Its Strong Share Price Run?

If you are wondering whether Winmark at around US$444 per share offers good value or if you might be arriving late, this piece lays out the key facts so you can judge the price for yourself. The stock has recently moved 3.2% over the last 7 days, with a 1 year return of 37.5% and 10.6% year to date. The 30 day return sits at a 1.2% decline and the 3 and 5 year returns are 46.1% and 163.2% respectively. Recent attention around Winmark has focused on its position in the Specialty Retail space...
NasdaqGM:NNNN
NasdaqGM:NNNNBiotechs

Anbio Biotechnology Broadens Test Portfolio And Shifts Risk Profile

Anbio Biotechnology, NasdaqGM:NNNN, is expanding beyond COVID-19 diagnostics into a broader test portfolio. The company is rolling out new rapid immunoassay and PCR platforms across human health, veterinary, and multi-disease applications. This move reflects a business model shift toward more diversified diagnostic revenues and reduced reliance on legacy COVID-19 products. For you as an investor, this repositioning matters because Anbio Biotechnology is moving from a single product focus...
NYSE:PRGO
NYSE:PRGOPharmaceuticals

Is Perrigo (PRGO) Pricing Reflect Its Recent Rebound And Weak Long Term Returns

Wondering whether Perrigo's current share price makes sense or if the market has mispriced it? This article walks through the key valuation clues that can help you frame that question. The stock has seen a 0.1% move over the last 7 days and a 16.8% return over the past month, set against a much tougher picture with a 21.8% decline year to date and a 52.9% fall over the last year, as well as 65.7% and 68.3% declines over 3 and 5 years respectively. Recent attention on Perrigo has focused less...
NasdaqCM:ASPI
NasdaqCM:ASPIChemicals

ASP Isotopes (ASPI) Revenue Surge Tests Bullish Growth Narratives Against Deepening Losses

ASP Isotopes (ASPI) has just put out its FY 2025 numbers, with Q4 revenue of about US$16.7 million and a Q4 basic EPS loss of US$0.76. Trailing twelve month revenue sits at roughly US$23.8 million against a TTM basic EPS loss of US$2.11. The company has seen quarterly revenue move from around US$1.2 million in Q4 FY 2024 to US$16.7 million in Q4 FY 2025, while trailing twelve month revenue shifted from about US$4.1 million to US$23.8 million over the same window. Investors will now be...
NYSE:U
NYSE:USoftware

Unity’s AI Ads Pivot Puts Vector And Meta Partnership In Focus

Unity Software (NYSE:U) is pivoting its ads business toward AI, positioning the Vector ad platform as its primary growth driver. The company is sunsetting the legacy ironSource Ads Network and is exploring a sale of its Supersonic publishing unit. Management expects Vector to reach a billion dollar annual run rate, with recent trends supporting upgrades to company guidance. Unity Software enters this shift with a share price of $21.62 and a mixed return profile, including a 51.1% decline...
NasdaqGM:ANL
NasdaqGM:ANLBiotechs

Adlai Nortye (ANL) Loss Narrows To US$18.3 Million Challenging Bearish Cash Burn Narrative

Adlai Nortye (NasdaqGM:ANL) has posted its FY 2025 first half results with total revenue of effectively US$0, a basic EPS loss of US$0.57 and net income loss of US$18.34 million, keeping the story firmly about cash burn and margins rather than top line scale. The company has seen recent periods marked by similarly low reported revenue, with basic EPS losses of US$0.64 and US$1.06 and net income losses of US$24.26 million and US$27.61 million across the two halves of FY 2024. As a result,...
NYSE:JXN
NYSE:JXNDiversified Financial

Assessing Jackson Financial (JXN) Valuation After Leadership Changes At PPM America And Jackson National

Jackson Financial (JXN) is in focus after the company reshaped its leadership by naming Christopher A. Raub as President and CEO of asset manager PPM America and adjusting roles at Jackson National Life Insurance Company. See our latest analysis for Jackson Financial. Recent leadership changes come as Jackson Financial’s share price has eased in the short term, with a 30 day share price return showing a 5.21% decline and a 90 day share price return showing a 13.41% decline. At the same time,...
NYSE:BY
NYSE:BYBanks

A Look At Byline Bancorp (BY) Valuation As New Shelf Registration Expands Capital Flexibility

What Byline Bancorp’s new shelf registration could mean for investors Byline Bancorp (BY) has filed an omnibus shelf registration covering common and preferred stock, depositary shares, debt securities, warrants, purchase contracts, and units. This gives the bank board-authorized flexibility to raise capital over time. See our latest analysis for Byline Bancorp. Byline Bancorp’s latest share price of US$33.15 sits against a 30 day share price return of 8.3% and year to date share price return...
NYSE:FLOC
NYSE:FLOCEnergy Services

Is Flowco Holdings' (FLOC) ESOP Shelf Registration Quietly Rewriting Its Capital Structure Story?

In April 2026, Flowco Holdings Inc. filed a shelf registration to offer 1,454,849 shares of Class A common stock, totaling about US$29.97 million, in connection with an ESOP-related transaction. This ESOP-focused shelf registration highlights a potential shift in Flowco’s capital structure and underscores the company’s emphasis on broadening employee ownership. We’ll now examine how this ESOP-related shelf registration might reshape Flowco’s investment narrative, particularly around capital...
NasdaqGM:ZNTL
NasdaqGM:ZNTLBiotechs

Is Zentalis (ZNTL) Using Azenosertib’s New Dose To Reframe Its Ovarian Cancer Strategy?

Zentalis Pharmaceuticals recently reported that a 400mg once-daily, 5-days-on/2-days-off regimen of azenosertib was selected as the optimal monotherapy dose for Cyclin E1-positive platinum-resistant ovarian cancer, following a prespecified interim analysis from the DENALI Part 2a Phase 2 trial. This dose decision, supported by a differentiated response rate, comparable safety and plans for inclusion in both the pivotal DENALI Phase 2 and confirmatory ASPENOVA Phase 3 trials, is central to...